Comparative Pharmacology
Head-to-head clinical analysis: ERYC versus ERYPED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC versus ERYPED.
ERYC vs ERYPED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It is a macrolide antibiotic.
250-500 mg orally every 6 hours or 333-500 mg orally every 8 hours; maximum 4 g/day.
250–500 mg orally every 6 hours or 500–1000 mg intravenously every 6 hours; maximum 4 g/day.
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 4–8 hours in severe hepatic impairment; does not significantly change in renal failure.
2-4 hours (prolonged to 4-6 hours in neonates and patients with hepatic impairment); requires q6h dosing for most indications.
Primarily biliary excretion of unchanged drug (60–80%); renal excretion accounts for 10–15% of an oral dose, with minimal fecal elimination (<5%).
Primarily hepatic (biliary excretion of unchanged drug and metabolites); approximately 5% renal excretion as unchanged drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic